{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:21Z","timestamp":1790082921576,"version":"4.0.1"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008697","name":"University of Karachi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.biopha.2026.119901","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T22:40:15Z","timestamp":1788561615000},"page":"119901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preclinical evaluation of entecavir as a fetal hemoglobin inducer using in vitro, in vivo, network pharmacology, and molecular docking approaches"],"prefix":"10.1016","volume":"203","author":[{"given":"Junaid","family":"Ullah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Ghulam","family":"Musharraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.biopha.2026.119901_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/gim.2016.173","article-title":"\u03b2-Thalassemia","volume":"19","author":"Origa","year":"2017","journal-title":"Genet. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/ehm.09.74","article-title":"Global burden, distribution and prevention of \u03b2-thalassemias and hemoglobin E disorders","volume":"3","author":"Colah","year":"2010","journal-title":"Expert. Rev. Hematol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib3","doi-asserted-by":"crossref","first-page":"a011775","DOI":"10.1101\/cshperspect.a011775","article-title":"The prevention of thalassemia","volume":"3","author":"Cao","year":"2013","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.biopha.2026.119901_bib4","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2471\/BLT.06.036673","article-title":"and M. Darlison, Global epidemiology of haemoglobin disorders and derived service indicators.","volume":"86","author":"Modell","year":"2008","journal-title":"Bull. World Health Organ."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia","volume":"12","author":"Cao","year":"2010","journal-title":"Genet. Med."},{"issue":"7521","key":"10.1016\/j.biopha.2026.119901_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nature13614","article-title":"HSP70 sequestration by free \u03b1-globin promotes ineffective erythropoiesis in \u03b2-thalassaemia","volume":"514","author":"Arlet","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","article-title":"Beta-thalassemia","volume":"12","author":"Cao","year":"2010","journal-title":"Genet. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119901_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/bmt.2008.165","article-title":"Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT","volume":"42","author":"Cheuk","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.biopha.2026.119901_bib9","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-981-10-3701-6_21","article-title":"Allogeneic stem cell transplantation for thalassemia major","author":"Mathews","year":"2017","journal-title":"Regen. Med. Lab. Clin."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40291-019-00383-4","article-title":"Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges","volume":"23","author":"Ghiaccio","year":"2019","journal-title":"Mol. Diagn. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3324\/haematol.2015.141200","article-title":"Cure for thalassemia major\u2013from allogeneic hematopoietic stem cell transplantation to gene therapy","volume":"102","author":"Srivastava","year":"2017","journal-title":"haematologica"},{"issue":"6","key":"10.1016\/j.biopha.2026.119901_bib12","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1002\/jcp.26292","article-title":"Pharmacological and molecular approaches for the treatment of \u03b2-hemoglobin disorders.","volume":"233","author":"Lohani","year":"2018","journal-title":"J. Cell. Physiol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.hemonc.2017.02.002","article-title":"Hydroxyurea for nontransfusion-dependent \u03b2-thalassemia: a systematic review and meta-analysis","volume":"10","author":"Algiraigri","year":"2017","journal-title":"Hematol. \/Oncol. stem Cell. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/pbc.24178","article-title":"Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children","volume":"59","author":"Strouse","year":"2012","journal-title":"Pediatr. blood & Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119901_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/13543784.12.4.683","article-title":"Entecavir: a potent new antiviral drug for hepatitis B","volume":"12","author":"Honkoop","year":"2003","journal-title":"Expert. Opin. Investig. Drugs"},{"issue":"11","key":"10.1016\/j.biopha.2026.119901_bib16","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1185\/030079905X65268","article-title":"A review of entecavir in the treatment of chronic hepatitis B infection","volume":"21","author":"Rivkin","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"issue":"11-12","key":"10.1016\/j.biopha.2026.119901_bib17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jchromb.2011.02.023","article-title":"LC\u2013ESI-MS\/MS method for the quantification of entecavir in human plasma and its application to bioequivalence study","volume":"879","author":"Challa","year":"2011","journal-title":"J. Chromatogr. B"},{"issue":"11","key":"10.1016\/j.biopha.2026.119901_bib18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/0091270006293304","article-title":"Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects","volume":"46","author":"Yan","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119901_bib19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/BF02007714","article-title":"Efficient cell proliferation and predominant accumulation of \u025b-globin mRNA in human leukemic K562 cells which produce mostly Hb Gower 1","volume":"41","author":"Gambari","year":"1985","journal-title":"Experientia"},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.ima03bs21","article-title":"Trypan blue exclusion test of cell viability","volume":"21","author":"Strober","year":"1997","journal-title":"Curr. Protoc. Immunol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119901_bib21","doi-asserted-by":"crossref","first-page":"5421","DOI":"10.1046\/j.1432-1327.2000.01606.x","article-title":"Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity","volume":"267","author":"O'brien","year":"2000","journal-title":"Eur. J. Biochem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119901_bib22","first-page":"2001","article-title":"Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin","volume":"101","author":"Witt","year":"2003","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.biopha.2026.119901_bib23","doi-asserted-by":"crossref","unstructured":"Samid, D., A. Yeh, and P. Prasanna, Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. 1992.","DOI":"10.1182\/blood.V80.6.1576.bloodjournal8061576"},{"issue":"6","key":"10.1016\/j.biopha.2026.119901_bib24","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot5439","article-title":"Purification of RNA using TRIzol (TRI reagent)","volume":"2010","author":"Rio","year":"2010","journal-title":"Cold Spring Harb. Protoc."},{"issue":"4","key":"10.1016\/j.biopha.2026.119901_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2\u2212\u0394\u0394CT Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.biopha.2026.119901_bib26","series-title":"An introduction to performing immunofluorescence staining","author":"Im","year":"2019"},{"issue":"31","key":"10.1016\/j.biopha.2026.119901_bib27","doi-asserted-by":"crossref","first-page":"17551","DOI":"10.1039\/C9RA01744E","article-title":"Cinchona alkaloids as natural fetal hemoglobin inducing agents in human erythroleukemia cells","volume":"9","author":"Iftikhar","year":"2019","journal-title":"RSC Adv."},{"issue":"4","key":"10.1016\/j.biopha.2026.119901_bib28","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"Charan","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"issue":"110","key":"10.1016\/j.biopha.2026.119901_bib29","first-page":"53936","article-title":"Murine hind limb long bone dissection and bone marrow isolation","author":"Amend","year":"2016","journal-title":"J. Vis. Exp. JoVE"},{"issue":"D1","key":"10.1016\/j.biopha.2026.119901_bib30","doi-asserted-by":"crossref","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119901_bib31","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: a software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib32","doi-asserted-by":"crossref","first-page":"e01328-21","DOI":"10.1128\/spectrum.01328-21","article-title":"Long-term hepatitis B virus infection induces cytopathic effects in primary human hepatocytes, and can be partially reversed by antiviral therapy","volume":"10","author":"Zai","year":"2022","journal-title":"Microbiol. Spectr."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3390\/ph19020239","article-title":"Design and synthesis of 4-arylazo pyrazole carboxamides as dual AChE\/BChE inhibitors: kinetic and in silico evaluation","volume":"19","author":"Akocak","year":"2026","journal-title":"Pharmaceuticals"},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib34","article-title":"Network pharmacology and molecular docking approach to elucidate potential phytocompounds, targets, and mechanisms of Glycyrrhiza glabra in the alleviation of cellular senescence","volume":"4","author":"Sharma","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.biopha.2026.119901_bib35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejphar.2019.05.027","article-title":"Thiourea derivatives induce fetal hemoglobin production in-vitro: A new class of potential therapeutic agents for \u03b2-thalassemia","volume":"855","author":"Ali","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3390\/thalassrep13030017","article-title":"Understanding the intricacies of iron overload associated with \u03b2-thalassemia: a comprehensive review","volume":"13","author":"Basu","year":"2023","journal-title":"Thalass. Rep."},{"issue":"13","key":"10.1016\/j.biopha.2026.119901_bib37","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1182\/bloodadvances.2020003680","article-title":"Wild-type HIV infection after treatment with lentiviral gene therapy for \u03b2-thalassemia","volume":"5","author":"Hongeng","year":"2021","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.biopha.2026.119901_bib38","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/mt.2010.184","article-title":"Gene therapy and bone marrow transplantation for thalassemia: changing of the guard?","volume":"18","author":"Walters","year":"2010","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119901_bib39","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1182\/blood-2003-01-0117","article-title":"Hydroxyurea can eliminate transfusion requirements in children with severe \u03b2-thalassemia","volume":"102","author":"Bradai","year":"2003","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/j.1749-6632.1985.tb17189.x","article-title":"Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe \u03b2-thalassemia.","volume":"445","author":"Nienhuis","year":"1985","journal-title":"Ann. New. Y. Acad. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119901_bib41","first-page":"2708","article-title":"A pilot study of subcutaneous decitabine in \u03b2-thalassemia intermedia","volume":"118","author":"Olivieri","year":"2011","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"13","key":"10.1016\/j.biopha.2026.119901_bib42","first-page":"4640","article-title":"Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo","volume":"100","author":"Pace","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/10245330410001701512","article-title":"Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors","volume":"9","author":"Cao","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.biopha.2026.119901_bib44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00277-012-1671-3","article-title":"Hydroxyurea treatment in \u03b2-thalassemia patients: to respond or not to respond?","volume":"92","author":"Banan","year":"2013","journal-title":"Ann. Hematol."},{"issue":"21","key":"10.1016\/j.biopha.2026.119901_bib45","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1182\/blood.V124.21.4073.4073","article-title":"Are there true non-responders to hydroxyurea in sickle cell disease? A multiparameter analysis","volume":"124","author":"Chand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119901_bib46","series-title":"Medical Epigenetics","first-page":"585","article-title":"Chapter 32 - Pharmacoepigenomics","author":"Cacabelos","year":"2016"},{"issue":"11","key":"10.1016\/j.biopha.2026.119901_bib47","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1002\/ccr3.3141","article-title":"Challenges in transfusion and the role of Thalidomide in E-\u03b2-Thalassemia\u2014A case report","volume":"8","author":"Javed","year":"2020","journal-title":"Clin. Case Rep."},{"issue":"4","key":"10.1016\/j.biopha.2026.119901_bib48","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2004-02-0454","article-title":"Butyrate increases the efficiency of translation of \u03b3-globin mRNA","volume":"105","author":"Weinberg","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.biopha.2026.119901_bib49","doi-asserted-by":"crossref","DOI":"10.12688\/wellcomeopenres.17845.3","article-title":"A rational approach to drug repositioning in \u03b2-thalassemia: Induction of fetal hemoglobin by established drugs","volume":"7","author":"Prosdocimi","year":"2022","journal-title":"Wellcome Open. Res."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clinthera.2006.02.012","article-title":"Entecavir for the treatment of chronic hepatitis B virus infection","volume":"28","author":"Matthews","year":"2006","journal-title":"Clin. Ther."},{"key":"10.1016\/j.biopha.2026.119901_bib51","first-page":"176","article-title":"Antiviral agents","author":"Paintsil","year":"2019","journal-title":"Encycl. Microbiol."},{"key":"10.1016\/j.biopha.2026.119901_bib52","first-page":"1502","article-title":"Antiviral Agents","volume":"295","author":"Kimberlin","year":"2012"},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib53","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1665-2681(19)30861-0","article-title":"Efficacy and safety of long term entecavir in chronic hepatitis B treatment na\u00efve patients in clinical practice","volume":"13","author":"Ridruejo","year":"2014","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.biopha.2026.119901_bib54","doi-asserted-by":"crossref","unstructured":"Lozzio, C.B. and B.B. Lozzio, Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. 1975.","DOI":"10.1182\/blood.V45.3.321.321"},{"issue":"5702","key":"10.1016\/j.biopha.2026.119901_bib55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/278364a0","article-title":"Induction of erythroid differentiation in the human leukaemia cell line K562","volume":"278","author":"Andersson","year":"1979","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119901_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpan.2024.12.002","article-title":"Advances in drug discovery based on network pharmacology and omics technology","author":"Liu","year":"2024","journal-title":"Curr. Pharm. Anal."},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib57","doi-asserted-by":"crossref","first-page":"20594","DOI":"10.1038\/s41598-022-24385-1","article-title":"Disease-related compound identification based on deeping learning method","volume":"12","author":"Yang","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119901_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.888786","article-title":"Gene regulatory identification based on the novel hybrid time-delayed method","volume":"13","author":"Bao","year":"2022","journal-title":"Front. Genet."},{"issue":"2","key":"10.1016\/j.biopha.2026.119901_bib59","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/0115748936330499240909082529","article-title":"CLPr_in_ML: cleft lip and palate reconstructed features with machine learning","volume":"20","author":"Chen","year":"2025","journal-title":"Curr. Bioinforma."},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib60","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-024-01003-y","article-title":"Mechanisms and functions of SUMOylation in health and disease: a review focusing on immune cells","volume":"31","author":"Huang","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2026.119901_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2023.100128","article-title":"Preserving genome integrity: The vital role of SUMO-targeted ubiquitin ligases","volume":"2","author":"Han","year":"2023","journal-title":"Cell. Insight"},{"issue":"9","key":"10.1016\/j.biopha.2026.119901_bib62","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2443.2008.01216.x","article-title":"BCL11A is a SUMOylated protein and recruits SUMO-conjugation enzymes in its nuclear body.","volume":"13","author":"Kuwata","year":"2008","journal-title":"Genes. Cells"},{"issue":"6","key":"10.1016\/j.biopha.2026.119901_bib63","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ni925","article-title":"Bcl11a is essential for normal lymphoid development","volume":"4","author":"Liu","year":"2003","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119901_bib64","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/03630269.2018.1515774","article-title":"BCL11A down-regulation induces \u03b3-globin in human \u03b2-thalassemia major erythroid cells","volume":"42","author":"Li","year":"2018","journal-title":"Hemoglobin"},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2029392","article-title":"Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease","volume":"384","author":"Esrick","year":"2021","journal-title":"New. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/emm.2004.1","article-title":"Hypoxia-inducible factor (HIF-1) \u03b1: its protein stability and biological functions","volume":"36","author":"Lee","year":"2004","journal-title":"Exp. & Mol. Med."},{"issue":"5516","key":"10.1016\/j.biopha.2026.119901_bib67","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIF\u03b1 targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"issue":"7933","key":"10.1016\/j.biopha.2026.119901_bib68","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/s41586-022-05312-w","article-title":"Activation of \u03b3-globin expression by hypoxia-inducible factor 1\u03b1","volume":"610","author":"Feng","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2026.119901_bib69","first-page":"2140","article-title":"HIF\u2013prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques","volume":"110","author":"Hsieh","year":"2007","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"ement 1","key":"10.1016\/j.biopha.2026.119901_bib70","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1182\/blood-2022-164803","article-title":"Inhibition of hypoxia inducible factor prolyl hydroxylase by FG-4592 (roxadustat) increases erythropoietic stimulation in a mouse model of sickle cell disease","volume":"140","author":"Sharma","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.biopha.2026.119901_bib71","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1038\/s41598-019-48204-2","article-title":"Synergistic silencing of \u03b1-globin and induction of \u03b3-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for \u03b2-thalassaemia","volume":"9","author":"Mettananda","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2026.119901_bib72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/bjh.12814","article-title":"Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study","volume":"165","author":"Ronzoni","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119901_bib73","doi-asserted-by":"crossref","first-page":"584","DOI":"10.5152\/alphapsychiatry.2024.241642","article-title":"Exploring the Therapeutic Mechanism of Pingxin Dingzhi Decoction Through Network Pharmacology and Molecular Docking","volume":"25","author":"Ju","year":"2024","journal-title":"Alpha Psychiatry"},{"issue":"3","key":"10.1016\/j.biopha.2026.119901_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24342","article-title":"Network pharmacology combined with molecular docking simulations reveal the mechanism of action of Glycyrrhiza for treating pneumonia","volume":"116","author":"Yang","year":"2024","journal-title":"Pept. Sci."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226009376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:56:37Z","timestamp":1790081797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226009376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":74,"alternative-id":["S0753332226009376"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119901","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of entecavir as a fetal hemoglobin inducer using in vitro, in vivo, network pharmacology, and molecular docking approaches","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119901"}}